CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 439 filers reported holding CRISPR THERAPEUTICS AG in Q2 2022. The put-call ratio across all filers is 1.02 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $211 | -5.8% | 3,767 | -24.0% | 0.01% | -9.1% |
| Q1 2023 | $224 | -99.9% | 4,955 | -12.4% | 0.01% | -47.6% |
| Q3 2022 | $370,000 | -30.1% | 5,656 | -35.0% | 0.02% | -27.6% |
| Q2 2022 | $529,000 | -3.1% | 8,699 | 0.0% | 0.03% | +16.0% |
| Q1 2022 | $546,000 | -21.8% | 8,699 | -5.5% | 0.02% | -16.7% |
| Q4 2021 | $698,000 | -24.8% | 9,205 | +11.0% | 0.03% | -31.8% |
| Q3 2021 | $928,000 | -33.0% | 8,295 | -3.1% | 0.04% | -32.3% |
| Q2 2021 | $1,385,000 | +31.3% | 8,558 | -1.2% | 0.06% | +12.1% |
| Q1 2021 | $1,055,000 | – | 8,659 | – | 0.06% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 498,558 | $27,989,046 | 33.20% |
| Gilfoyle Management LLC | 100 | $4,842 | 15.90% |
| NEA Management Company, LLC | 1,587,854 | $89,142,124 | 6.80% |
| ARK Investment Management | 7,338,447 | $411,980,394 | 2.73% |
| Nikko Asset Management Americas, Inc. | 3,533,357 | $198,327,328 | 2.09% |
| Del-Sette Capital Management, LLC | 33,661 | $1,889,729 | 1.79% |
| Ikarian Capital, LLC | 200,000 | $11,228,000 | 1.79% |
| Ikarian Capital, LLC | 200,000 | $11,228,000 | 1.79% |
| Merlin Capital, Inc | 8,802 | $494,144 | 1.67% |
| Green Alpha Advisors, LLC | 34,373 | $1,929,700 | 1.27% |